Many women notice changes in their vagina, vulva and bladder (the urogenital area) during and after the menopause. Vulvovaginal atrophy (VVA, also known as urogenital atrophy or genitourinary syndrome of menopause (GSM)) is a common and under-reported menopausal condition arising from decreased oestrogenisation of the vaginal tissue.
The comparison table in this resource has been created by consensus by the PCWHF. It compares the different types of treatment for VVA, including useful expert notes agreed by GPs and menopause specialists working in primary care.
This resource provides useful advice on treatment options and support.
This resource was funded by an unrestricted educational grant from Flynn Pharma Ltd. Flynn has had no influence over the content. This resource is not intended to replace the need to apply clinical judgement on a case-by-case basis.